Diabetes Metab J > Volume 44(4); 2020 > Article
Lee, Kim, Kim, Lee, Cho, Lee, Yim, Yoon, and Kim: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence



Some patients admitted to hospitals for glycemic control experience hypoglycemia despite regular meals and despite adhering to standard blood glucose control protocols. Different factors can have a negative impact on blood glucose control and prognosis after discharge. This study investigated risk factors for hypoglycemia and its effects on glycemic control during the hospitalization of patients in the general ward.


This retrospective study included patients who were admitted between 2009 and 2018. Patients were provided regular meals at fixed times according to ideal body weights during hospitalization. We categorized the patients into two groups: those with and those without hypoglycemia during hospitalization.


Of the 3,031 patients, 379 experienced at least one episode of hypoglycemia during hospitalization (HYPO group). Hypoglycemia occurred more frequently particularly in cases of premixed insulin therapy. Compared with the control group, the HYPO group was older (61.0±16.8 years vs. 59.1±16.5 years, P=0.035), with more females (60.4% vs. 49.6%, P<0.001), lower body mass index (BMI) (23.5±4.2 kg/m2 vs. 25.1±4.4 kg/m2, P<0.001), and higher prevalence of type 1 diabetes mellitus (6.1% vs. 2.6%, P<0.001), They had longer hospital stay (11.1±13.5 days vs. 7.6±4.6 days, P<0.001). After discharge the HYPO group had lower glycosylated hemoglobin reduction rate (−2.0%±0.2% vs. −2.5%±0.1%, P=0.003) and tended to have more frequent cases of cardiovascular disease.


Hypoglycemia occurred more frequently in older female patients with lower BMI and was associated with longer hospital stay and poorer glycemic control after discharge. Therefore, clinicians must carefully ensure that patients do not experience hypoglycemia during hospitalization.


Diabetes mellitus (DM) has become increasingly more prevalent over the past several decades, with an estimated outbreak over 366 million by 2030 [1]. The long-term DM complications, induced by prolonged hyperglycemia, have been the major causes of premature mortality and morbidity [2,3,4]. Therefore, tight glycemic control may reduce the risk of progression to complications over time. Hypoglycemia is frequently accompanied by tight glycemic control with intensive antidiabetic therapy. However, several studies failed to investigate the conclusion that strict glycemic control targeting a glycosylated hemoglobin (HbA1c) level of <6.5% reduced the incidence of complications [5,6,7]. Additionally, hypoglycemia and all-cause mortality rates reportedly increased in the intensively controlled groups of some trials [6,7,8]. While hyperglycemia is the main cause of microvascular and macrovascular complications, hypoglycemia can cause a series of sequelae that can alter the patient's cardiovascular risk profile and increase mortality. Particularly, hypoglycemia in the intensive care unit (ICU) increases the risk of mortality, seizures, and coma; thus, careful monitoring for tight glycemic control is crucial [9]. However, studies performed in ICU patients may show overestimated results compared with those of analysis on general glycemic control. Most patients experiencing hypoglycemia encounter the condition in real life, not in the ICU. Furthermore, hypoglycemia outcomes in patients hospitalized only for glycemic control is less known.
Therefore, this study analyzed risk factors of hypoglycemia among patients who experienced and those who did not during hospitalization and the effect of hypoglycemia on clinical outcomes.


Study design and selection of participants

This was a retrospective study of electronic medical records (EMRs) of patients admitted for only glycemic control at the Department of Endocrinology and Metabolism of Seoul St. Mary's Hospital from January 2009 to July 2018. Patients diagnosed with DM and treated with oral hypoglycemic agents (OHAs) or insulins were selected. Patients with DM admitted for other reasons, such as frequent hypoglycemia due to DM-complications or gastrointestinal symptoms, were excluded. All OHAs and insulin orders were documented and reviewed during hospitalization. No other exclusion criteria were considered except for the cause of hospitalization. DM was defined using the International Classification of Diseases-10th Revision (ICD-10), as follows: E10 (type 1 DM [T1DM]), E11-E14 (type 2 DM [T2DM]), and O24 (DM in pregnancy).


Patients admitted for glycemic control underwent blood glucose measurement seven times a day: fasting glucose after overnight fasting (6:00 to 6:30 AM), preprandial glucose (before a meal), and postprandial glucose after 2 hours following meal initiation (10:00 to 10:30 AM, 2:30 to 3:00 PM, and 8:00 to 8:30 PM); additional glucose measurements were performed when patients felt hypoglycemic or at 3:00 AM when patients had a fasting glucose level <70 mg/dL. The hypoglycemia during hospitalization (HYPO group) comprised patients experiencing at least one hypoglycemia episode during hospitalization, whereas the control group comprised patients treated without experiencing hypoglycemia during hospitalization. Hypoglycemia was defined as blood glucose level <70 mg/dL based on the value checked after admission [10]. After admission, insulin dose was increased or decreased appropriately according to the guidelines [11].

Outcome measures

On admission, data on basic characteristics, including age, sex, height, weight, and body mass index (BMI), were extracted. Blood chemistry results were reviewed based on EMRs. HbA1c, C-peptide, insulin, blood urea nitrogen (BUN), creatinine, glomerular filtration rate (GFR), sodium, potassium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase, lactate dehydrogenase, amylase, lipase, erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hsCRP), alkaline phosphatase, gamma-glutamyl transpeptidase (γ-GTP), total cholesterol (TC), triglycerides, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), and osmolality values were evaluated. All measurements were performed with an automated blood chemistry analyzer (Hitachi 747; Hitachi, Tokyo, Japan). HbA1c was measured by high-performance liquid chromatography using Diabetes Control and Complications Trial-aligned methods (Tosoh-G8; Tosoh, Tokyo, Japan). Homeostatic model assessment of insulin resistance (HOMA-IR) and homeostatic model assessment of beta-cell function (HOMA-β) as insulin resistance markers were calculated as follows [12]:
HOMA-IR=[fasting insulin (IU/mL)×fasting plasma glucose (mmol/L)]/22.5
HOMA-β=[20×fasting plasma insulin (IU/mL)]/[fasting plasma glucose (mmol/L)−3.5]
We extracted data on all OHAs and insulin types that were prescribed during the patient's hospitalization. Insulin was categorized into basal insulin (glargine, detemir, and degludec), bolus insulin (aspart, lispro, and glulisine), and premixed insulin. OHAs were divided into metformin, dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium-glucose cotransporter-2 inhibitors (SGLT2i), while treatment modalities were classified according to the combination of insulin and OHAs. The ICD-10 was used to confirm the presence of current comorbidities, as follows: I10-I15 (hypertensive disease); I20 (angina pectoris); I21 (acute myocardial infarction [AMI]); I20-I25 (ischemic heart disease [IHD]); I60-I69 (cerebrovascular disease [CVD]); C (cancer); I50, I11.0, I13.0, and I24.8 (heart failure); and I12, I13, and N17-N19 (renal failure). The initial diagnosis date of these diagnoses was examined to determine whether the diagnosis was a current coexisting disease or a disease occurring after discharge.

Direct chart review and data quality management

A direct chart review was conducted to determine if patients were hospitalized for glycemic control. We excluded patients admitted for perioperative glycemic control and admitted due to other diseases but had high blood glucose levels. To confirm the extracted data, one researcher modified the data through direct chart review. The modified data were stored separately and processed using the same protocol.

Privacy protection

All identifiable information, including patient's name and social security number were made anonymous. The patient's hospital registration number was assigned a temporary number by a responsible investigator, and after the analysis, the registration number was deleted. The comparison of the hospital registration number with the temporary number was accessible only to the responsible investigator. If a chart review was required after statistical processing, the responsible investigator could access the hospital information. All data were stored in an encrypted computer in the form of encrypted files, which were accessible only to the responsible investigator. This study used EMRs of patients whose treatments were terminated, and thus, there was no physical or mental risk to the patients. Therefore, informed consent was not required. This study was approved by the Clinical Research Ethics Committee of the Catholic University of Korea (IRB no. KC18RNSI0379).

Primary data analysis

Baseline variables were presented as means and standard deviations or medians and interquartile ranges for continuous variables based on normality, and numbers and percentages for categorical variables. Hypoglycemia status was compared using the independent t-test or Wilcoxon rank-sum test for continuous variables and the chi-square or exact test for categorical variables. Differences in incidence ratio were determined by survival analysis using the log-rank test to compare hypoglycemic admission status and various disease entities. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). A P value of <0.05 was considered statistically significant.


In total, 3,862 patients were admitted for glycemic control between January 2009 and July 2018 at our department. Among them, 831 patients were hospitalized due to reasons besides glycemic control. Finally, 3,031 patients were included.

Baseline characteristics of study subjects

The mean age was 59.3±16.5 years (range, 42.8 to 75.8 years), and 50.9% (1,543/3,031) were female. The mean BMI was 24.9±4.4 kg/m2 (range, 20.5 to 29.3 kg/m2). Of 3,031 patients, 2,937 (96.9%) had diagnostic codes for T2DM, 91 (3.0%) for T1DM, and three (0.1%) for DM in pregnancy. Moreover, 50.7% of patients were treated with multiple insulin injections using basal and bolus insulin, while 8.0% (243/3,031) were prescribed with premixed insulin. The mean length of hospital stay was 8.0±6.5 days (Table 1).

Baseline characteristics according to hypoglycemia occurrence during hospitalization

Table 2 summarizes the demographic characteristics between the HYPO and control groups. Of 3,031 patients, 12.5% (379) experienced at least one episode of HYPO group, whereas 87.5% (2,652) were treated without experiencing hypoglycemia during the stay (control group). The HYPO group had significantly older age (61.0±16.8 years vs. 59.1±16.5 years, P=0.035), more females (60.4% vs. 49.6%, P<0.001), and significantly lower BMI (23.5±4.2 kg/m2 vs. 25.1±4.4 kg/m2, P<0.001). T1DM was more prevalent in the HYPO group (6.1% vs. 2.6%, P<0.001).

Treatment pattern in the HYPO and control groups

Regarding treatment pattern during hospital stay (Table 3), there were no significant differences in basal insulin (82.3% vs. 81.1%, P=0.571) and bolus insulin (53.8% vs. 51.9%, P=0.479) between both groups. There was also no significant difference in treatment with basal insulin+bolus insulin between both groups (53.0% vs. 50.4%, P=0.333). Use of treatment with a basal insulin+bolus insulin+metformin combination was significantly less common in the HYPO group (21.1% vs. 25.9%, P=0.043). Furthermore, there was no significant difference between both groups regarding treatment with basal insulin+bolus insulin+metformin combined with DPP4i (9.5% vs. 9.4%, P=0.964) and SGLT2i (0.3% vs. 1.1%, P=0.251). However, premixed insulin was significantly more used in the HYPO group (10.8% vs. 7.2%, P=0.012). Use of the regimen consisting of a premixed insulin and metformin combination was significantly more commonly used in the HYPO group (6.3% vs. 3.5%, P=0.008). We analyzed the association between hypoglycemia and treatment regimen using logistic regression analysis. The risk of hypoglycemia differed according to treatment regimen. Odds ratio (OR) was obtained by referring to OR of control group as 1.0. Hypoglycemia was prominent in those who used premixed insulin (OR, 1.57; 95% confidence interval [CI], 1.10 to 2.24; P=0.013) and premixed insulin with metformin (OR, 1.85; 95% CI, 1.17 to 2.95; P=0.009) (Supplementary Table 1).

Laboratory findings in the HYPO group

Those in the HYPO group had a lower HbA1c level than the control group, but there was no significant difference (10.0%±2.3% vs. 10.1%±2.3%, P=0.410) (Supplementary Table 2). C-peptide was significantly lower in the HYPO group (0.9 ng/mL [0.3 to 2.0] vs. 1.7 ng/mL [0.9 to 2.7], P<0.001). There were no significant differences in insulin (20 µIU/mL [11 to 42] vs. 18 µIU/mL [12 to 34], P=0.323), HOMA-IR (7 [3 to 19] vs. 8 [4 to 16], P=0.492), and HOMA-β (63 [21 to 205] vs. 61 [28 to 136], P=0.768). The mean AST (20 U/L [16 to 26] vs. 21 U/L [17 to 28], P=0.049), ALT (18 U/L [13 to 27] vs. 21 U/L [15 to 32], P<0.001), lipase (28 U/L [19 to 48] vs. 35 U/L [21 to 55], P=0.005), and γ-GTP (23 mg/dL [16 to 50] vs. 29 mg/dL [19 to 54], P<0.001) were significantly lower in the HYPO group than in the control group, but with no clinically meaningful differences. There were no significant differences in BUN and creatinine. However, the HYPO group showed significantly lower GFR than the control group (29.3±12.3 mL/min/1.73 m2 vs. 32.3±12.6 mL/min/1.73 m2, P<0.001). There were significantly more patients with a GFR of <30 mL/min/1.73 m2 in the HYPO group than in the control group (P=0.002) (Supplementary Table 3). In addition, there were no significant differences in ESR (19 mm/hr [10 to 38] vs. 17 mm/hr [9 to 33], P=0.077) and hsCRP (0.1 mg/dL [0.1 to 0.5] vs. 0.1 mg/dL [0.1 to 0.4], P=0.052). For lipid profiles, the HYPO group demonstrated significantly lower TC (156±51 mg/dL vs. 162±50 mg/dL, P=0.047), triglycerides (104 mg/dL [70 to 152] vs. 125 mg/dL [88 to 187], P<0.001), and LDL-C (85±39 mg/dL vs. 91±37 mg/dL, P=0.015) and significantly higher HDL-C (44±16 mg/dL vs. 40±12 mg/dL, P=0.001). Sodium (136±5 mEq/L vs. 137±5 mEq/L, P=0.001) and potassium (4.1 mEq/L [3.6 to 4.4] vs. 4.2 mEq/L [3.9 to 4.5], P<0.001) levels were significantly lower in the HYPO group; however, there was no clinically meaningful difference.

Comparison of comorbidities

For heart failure, there was no significant difference between both groups (5.5% vs. 5.6%, P=0.738). Hypertensive disease (41.2% vs. 38.7%, P=0.363), angina (13.5% vs. 13.5%, P=0.966), AMI (5.0% vs. 3.4%, P=0.124), IHD (20.8% vs. 18.6%, P=0.294), CVD (11.9% vs. 10.8%, P=0.525), and renal failure (9.2% vs. 7.3%, P=0.177) had higher prevalence in the HYPO group than in the control group; however, these results were not significant (Table 4).

Comparison of length of hospital stay and HbA1c after discharge

The mean length of hospital stay was significantly longer in the HYPO group than in the control group (11.1±13.5 days vs. 7.6±4.6 days, P<0.001) (Fig. 1A). Significant improvement in HbA1c after discharge was achieved in both the HYPO (from 10.0% to 8.0%, P<0.01) and control group (from 10.1% to 7.6%, P<0.01). However, the HYPO group showed less improvement in HbA1c than the control group (−2.0%±0.2% vs. −2.5%±0.1%, P=0.003) (Fig. 1B).

Two-year follow-up morbidity and hypoglycemia

Analyses of 2-year follow-up morbidity were performed (Fig. 2). The HYPO group showed higher incidence of heart failure (P=0.268) (Fig. 2A), hypertensive disease (P=0.703) (Fig. 2B), angina (P=0.545) (Fig. 2C), AMI (P=0.103) (Fig. 2D), IHD or CVD (P=0.622) (Fig. 2E), and renal failure (P=0.265) (Fig. 2F) than the control group; however, there were no significant differences.


Hypoglycemia is a crucial complication of intensive glycemic control. Severe hypoglycemia is associated with increased risk of microvascular and macrovascular complications, including cardiovascular disease and non-cardiovascular disease [5,6]. Moreover, hypoglycemia induces poor outcomes in hospitalized patients [13]. Inpatient hypoglycemia is correlated with longer length of hospital stay and increased mortality [14,15]. We revealed that an experience of hypoglycemia during hospitalization affected the length of hospital stay and poorly controlled the HbA1c level.
Hypoglycemia acts as a barrier to insulin therapy for glycemic control. Basal insulin and premixed insulin reduced HbA1c level by a similar amount, and hypoglycemia risk was higher with premixed insulin [16,17,18]. Premixed insulin is usually preferred to reduce the inconvenience of multiple injections compared with basal-bolus insulin injection. Premixed insulin may be beneficial in controlling postprandial glucose, but it can be applied mainly to patients with constant, regular meals and meal volume [19,20,21,22]. When variations in blood glucose control arise due to irregular meals or when food intake is impossible, premixed insulin often induces hypoglycemia [23]. In our study, hospitalized patients were provided with regular meals according to adjusted calories, and insulin dose was determined according to protocol. However, the hypoglycemia rate was high in the case of premixed insulin treatment in this study. It is also important to consider the possibility of differences between individual characteristics. These are the reasons why personalized treatment is necessary. In fact, in this study, the frequency of hypoglycemia was higher in older and leaner females. Another reason could be insufficient medical management for increasing insulin by the clinician. Clinicians have less experience with premixed insulin than with basal or bolus insulin [24,25,26].
Older age is an important factor of hypoglycemia. Premixed insulin causes hypoglycemia more frequently in the elderly [27]. In our results, in-hospital hypoglycemia was more common among older and female patients with lower BMI. Therefore, insulin selection is very crucial in reducing hypoglycemia among older females with low BMI.
In our study, glucose and C-peptide levels were significantly lower in the HYPO group, with no differences in HbA1c, HOMA-IR, and HOMA-β. Our results of lower C-peptide level and hypoglycemia are consistent with those of some studies on T1DM [28,29]. Meanwhile, lower C-peptide level and hypoglycemia in T2DM are less commonly studied. C-peptide is an amino acid that is a cleaved form of proinsulin [30]. Although previous studies have investigated that C-peptide has no glucose-lowering effect, C-peptide induces insulin action at lower levels of the hormone and inhibits insulin action at higher levels [31]. Hence, C-peptide might predict hypoglycemia. This study also presented that GFR could be a predictor of hypoglycemic events. With kidney dysfunction, OHAs and insulin can accumulate and increase the body's susceptibility to hypoglycemia. Moreover, kidney disease could impair glucose counter-regulation and reduce renal gluconeogenesis [32].
In the analysis of short-term follow-up after discharge, patients with hypoglycemia showed 146% longer hospital stay than those without hypoglycemia. This was consistent with the findings of other studies [33,34]. After hospitalization, HbA1c level was lower in patients without hypoglycemia than in those with hypoglycemia. Glycemic control analyzed based on differences in HbA1c levels was better among patients without hypoglycemia than among those with hypoglycemia. The effect of glycemic control on admission was apparent in both groups. If hypoglycemia affected the course of treatments for hypoglycemia itself, the delay would have to prolong the length of hospital stay. Hypoglycemia is correlated with cardiovascular mortality in insulin-treated patients [35]. Likewise, in our study, patients in the HYPO group showed higher incidence for hypertensive disease, AMI, IHD, CVD, and stage 4 kidney disease, reflecting a greater tendency for cardiovascular disease. Since our study period (2 years) was short for analyzing outcomes, little significant difference was found between patients with hypoglycemia and those without hypoglycemia. Moreover, this study did not focus on ICU patients but focused on patients hospitalized only for glycemic control. Thus, further research involving a large number of patients and a longer follow-up period will be needed.
This study has some limitations. As this study was based on retrospective data obtained from only one hospital, we could not confirm a causal relationship between hypoglycemia and various risk factors or occurrence of cardiovascular disease. Furthermore, the diagnostic data were based on ICD-10 codes; therefore, misclassification may have occurred, including failure to classify other diagnoses unrelated to DM due to the research focus on hypoglycemia. Although, it is possible that alteration of the post-discharge treatment regimen affected HbA1c levels, the treatment regimen used after discharge was not analyzed in the current study because of limitations of the data.
The greatest advantage of this EMR-based retrospective study is that it used real-world evidence (RWE) based on real-world data obtained from real practice. This study was conducted in patients experiencing hypoglycemia rather than in ICU patients only. The results of randomized controlled trials and RWE differ significantly when applied in actual practice, including when assessing the actual effects of treatment [36]. RWE can be used to judge the current treatment situation because it reflects the actual treatment field [37]. Although our results showed a tendency to agree with the results of most previous studies, it is worth noting that premixed insulin-induced hypoglycemia occurred more often in leaner and older females and was associated with poor outcomes in terms of length of hospital stay and glycemic control. Therefore, clinicians should focus on preventing hypoglycemia during hospitalization when prescribing premixed insulin.
In summary, the frequency of hypoglycemia during hospitalization was higher among older and leaner females. Hypoglycemia also correlated with increased length of hospital stay and poorly controlled hyperglycemia. This study was based on RWE regarding hypoglycemia, and therefore the findings could be applicable to patients with DM in real life. While there was lack of causative factors for increased cardiovascular morbidity in our data, our findings support the trend of increased cardiovascular morbidity among patients who experience hypoglycemia. However, further research with a longer study period and larger sample size is required to identify whether hypoglycemia among inpatients is associated with adverse outcomes after discharge.


This research was supported by a grant from the Korea Institute of Drug Safety and Risk Management in 2018.


CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.


  • Conception or design: J.L., H.S.K.

  • Acquisition, analysis, or interpretation of data: T.M.K., H.K., S.H.L., J.H.C., H.L., H.W.Y., K.H.Y.

  • Drafting the work or revising: J.L.

  • Final approval of the manuscript: H.S.K.


Supplementary materials related to this article can be found online at https://doi.org/10.4093/dmj.2019.0064.

Supplementary Table 1

The association between hypoglycemia and treatment regimens

Supplementary Table 2

Laboratory findings in the hypoglycemia group and control group

Supplementary Table 3

The association between hypoglycemic status and baseline variables


1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
3. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978-982.
4. Foo K, Cooper J, Deaner A, Knight C, Suliman A, Ranjadayalan K, Timmis AD. A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart 2003;89:512-516.
5. ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
7. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
8. de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, MacMahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M. ADVANCE Collaborative group. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease. Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 2009;52:2328-2336.
crossref pdf
9. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007;35:2262-2267.
10. Rasooly RS, Akolkar B, Spain LM, Guill MH, Del Vecchio CT, Carroll LE. The National Institute of Diabetes and Digestive and Kidney Diseases Central Repositories: a valuable resource for nephrology research. Clin J Am Soc Nephrol 2015;10:710-715.
11. Lee BW, Kim JH, Ko SH, Hur KY, Kim NH, Rhee SY, Kim HJ, Moon MK, Park SO, Choi KM. Committee of Clinical Practice Guideline of Korean Diabetes Association. Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. Korean J Intern Med 2017;32:967-973.
crossref pdf
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
crossref pdf
13. Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes: a systematic review. Cardiovasc Diabetol 2013;12:135.
14. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011;34:1164-1170.
15. Timmons JG, Cunningham SG, Sainsbury CA, Jones GC. Inpatient glycemic variability and long-term mortality in hospitalized patients with type 2 diabetes. J Diabetes Complications 2017;31:479-482.
16. Yki-Jarvinen H, Dressler A, Ziemen M. HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.
17. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
18. Singhai A, Banzal S, Joseph D, Jha RK, Jain P. Comparison of insulin glargine with human premix insulin in patients with type 2 diabetes inadequately controlled on oral hypoglycemic drugs in a 24-week randomized study among Indian population. Indian J Clin Pract 2013;2:619-623.
19. Hermansen K, Colombo M, Storgaard H, OStergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002;25:883-888.
20. Malone JK, Yang H, Woodworth JR, Huang J, Campaigne BN, Halle JP, Yale JF, Grossman LD. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab 2000;26:481-487.
21. Coscelli C, Iacobellis G, Calderini C, Carleo R, Gobbo M, Di Mario U, Leonetti F, Galluzzo A, Pirrone V, Lunetta M, Casale P, Paleari F, Falcelli C, Valle D, Camporeale A, Merante D. Importance of premeal injection time in insulin therapy: humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 2003;40:187-192.
crossref pdf
22. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005;22:374-381.
23. Mattoo V, Milicevic Z, Malone JK, Schwarzenhofer M, Ekangaki A, Levitt LK, Liong LH, Rais N, Tounsi H. Ramadan Study Group. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003;59:137-143.
24. Wu T, Betty B, Downie M, Khanolkar M, Kilov G, Orr-Walker B, Senator G, Fulcher G. Practical guidance on the use of premix insulin analogs in initiating, intensifying, or switching insulin regimens in type 2 diabetes. Diabetes Ther 2015;6:273-287.
crossref pdf
25. Tambascia MA, Nery M, Gross JL, Ermetice MN, de Oliveira CP. Evidence-based clinical use of insulin premixtures. Diabetol Metab Syndr 2013;5:50.
crossref pdf
26. Kalra S, Gupta Y, Unnikrishnan AG. Flexibility in insulin prescription. Indian J Endocrinol Metab 2016;20:408-411.
27. Ligthelm RJ, Kaiser M, Vora J, Yale JF. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc 2012;60:1564-1570.
28. Lachin JM, McGee P, Palmer JP. DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748.
29. Kuhtreiber WM, Washer SL, Hsu E, Zhao M, Reinhold P 3rd, Burger D, Zheng H, Faustman DL. Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med 2015;32:1346-1353.
30. Li ZG, Qiang X, Sima AA, Grunberger G. C-peptide attenuates protein tyrosine phosphatase activity and enhances glycogen synthesis in L6 myoblasts. Biochem Biophys Res Commun 2001;280:615-619.
31. Grunberger G, Sima AA. The C-peptide signaling. Exp Diabesity Res 2004;5:25-36.
crossref pdf
32. Alsahli M, Gerich JE. Hypoglycemia in patients with diabetes and renal disease. J Clin Med 2015;4:948-964.
33. Nirantharakumar K, Marshall T, Kennedy A, Narendran P, Hemming K, Coleman JJ. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabet Med 2012;29:e445-e448.
34. McKechnie J, Maitland R, Sainsbury CAR, Jones GC. Admission glucose number (AGN): a point of admission score associated with inpatient glucose variability, hypoglycemia, and mortality. J Diabetes Sci Technol 2019;13:213-220.
35. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
36. Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 2017;40:1425-1432.
37. Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci 2018;33:e213.
Fig. 1

Comparison of (A) length of hospital stay and (B) glycosylated hemoglobin (HbA1c) level after discharge between patients with and without hypoglycemia. aDenotes a statistically significant difference in length of hospital stay between hypoglycemic group and control group (P=0.01).

Fig. 2

Kaplan-Meier survival curves for (A) heart failure, (B) hypertensive disease, (C) angina, (D) acute myocardial infarction, (E) ischemic heart disease, and (F) renal failure among patients with and without hypoglycemia.

Table 1

Baseline characteristics of patients (n=3,031)

Values are presented as mean±standard error or number (%).

BMI, body mass index; DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor.

Characteristic Value
Age, yr 59.3±16.5
Female sex 1,543 (50.9)
Height, cm 162.1±9.4
Weight, kg 65.8±14.7
BMI, kg/m2 24.9±4.4
Type of diabetes
 Type 1 diabetes mellitus 91 (3.0)
 Type 2 diabetes mellitus 2,937 (96.9)
 Diabetes mellitus in pregnancy 3 (0.1)
 Basal insulin 2,463 (81.3)
 Bolus insulin 1,580 (52.1)
 Basal insulin+bolus insulin 1,537 (50.7)
 Basal insulin+bolus insulin+metformin 768 (25.3)
 Basal insulin+bolus insulin+metformin+DPP4i 286 (9.4)
 Basal insulin+bolus insulin+metformin+SGLT2i 29 (1.0)
 Premixed insulin 243 (8.0)
 Premixed insulin+metformin 117 (3.9)
 Premixed insulin+metformin+DPP4i 39 (1.3)
 Premixed insulin+metformin+SGLT2i 3 (0.1)
Length of hospital stay, day 8.0±6.5
Table 2

Demographic characteristics of the hypoglycemia group and control group

Values are presented as number (%) or mean±standard error.

Characteristic Hypoglycemia group Control group P value
Number 379 (12.5) 2,652 (87.5)
Age, yr 61.0±16.8 59.1±16.5 0.035
Female sex 229 (60.4) 1,314 (49.6) <0.001
Height, cm 160.0±9.0 162.4±9.5 <0.001
Weight, kg 60.2±12.9 66.5±14.8 <0.001
Body mass index, kg/m2 23.5±4.2 25.1±4.4 <0.001
Type of diabetes
 Type 1 diabetes mellitus 23 (6.1) 68 (2.6) <0.001
 Type 2 diabetes mellitus 356 (93.9) 2,581 (97.3) <0.001
 Diabetes mellitus in pregnancy 0 3 (0.1) >0.999
Table 3

Treatment pattern between the hypoglycemia group and control group

Values are presented as number (%).

DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor.

Variable Hypoglycemia group Control group P value
 Basal insulin 312 (82.3) 2,151 (81.1) 0.571
 Bolus insulin 204 (53.8) 1,376 (51.9) 0.479
 Basal insulin+bolus insulin 201 (53.0) 1,336 (50.4) 0.333
 Basal insulin+bolus insulin+metformin 80 (21.1) 668 (25.9) 0.043
 Basal insulin+bolus insulin+metformin+DPP4i 36 (9.5) 250 (9.4) 0.964
 Basal insulin+bolus insulin+metformin+SGLT2i 1 (0.3) 28 (1.1) 0.251
 Premixed insulin 41 (10.8) 190 (7.2) 0.012
 Premixed insulin+metformin 24 (6.3) 93 (3.5) 0.008
 Premixed insulin+metformin+DPP4i 7 (1.9) 32 (1.2) 0.325
 Premixed insulin+metformin+SGLT2i 0 3 (0.1) >0.999
Table 4

Comparison of comorbidities between the hypoglycemia group and control group

Values are presented as number (%).

AMI, acute myocardial infarction; IHD, ischemic heart disease; CVD, cerebrovascular disease.

Variable Total Hypoglycemia group Control group P value
Heart failure 169 (5.6) 21 (5.5) 148 (5.6) 0.975
Hypertensive disease 1,183 (39.0) 156 (41.2) 1,027 (38.7) 0.363
Angina 410 (13.5) 51 (13.5) 359 (13.5) 0.966
AMI 110 (3.6) 19 (5.0) 91 (3.4) 0.124
IHD 572 (18.9) 79 (20.8) 493 (18.6) 0.294
CVD 331 (10.9) 45 (11.9) 286 (10.8) 0.525
IHD+CVD 764 (25.2) 103 (27.2) 661 (24.9) 0.345
Renal failure 228 (7.5) 35 (9.2) 193 (7.3) 0.177
Cancer 304 (10.0) 34 (9.0) 270 (10.2) 0.463

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2021 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer